in the news

EndPoints News

Mariana Oncology, a radiopharma startup founded by top-tier VCs, nabs $175M Series B

Mariana Oncology, a biotech incubated by three prominent life sciences VC firms, closed a $175 million Series B round Thursday morning, as its first pipeline program prepares to begin human testing sometime next year. The startup, founded as Curie Therapeutics by Atlas Venture, RA Capital Management and Access Biotechnology, will focus that drug candidate in

More

Endpoints News

Day One Biopharmaceuticals inks research collaboration with Swedish biotech

Day One Biopharmaceuticals secured a research and licensing deal with Sprint Bioscience in a bid to build out its cancer-fighting arsenal. The Bay Area biotech is paying $3 million upfront for the global rights of one of Sprint’s cancer programs known as VADA, which is designed to target the protein known as vaccinia-related kinase 1

More

Endpoints News

Eli Lilly inks $2.4B cash deal to buy DICE and its immunology pipeline

Eli Lilly is joining the “blistering” pace of M&A this year as it bets $2.4 billion in cash on DICE Therapeutics, a publicly traded biotech with oral IL-17 inhibitors in the clinic. Lilly expects to pay $48.00 per share of DICE stock at a 40% 30-day premium, with the deal set to close in the

More

Endpoints News

Disc Medicine claims PhII win for repurposed ex-Roche drug in rare blood disorder

When Disc Medicine closed a $62.5 million raise led by Bain Capital earlier this year, the biotech’s CEO John Quisel pointed to the stream of clinical readouts in blood disorders it is expecting as the impetus. Now, it’s outlining the first of those data — with an open-label Phase II trial providing what it calls

More

Endpoints News

Acelyrin sets out for a 2021-sized IPO for California biotech’s PhIII drug

Drug licensor and developer Acelyrin revealed more of its IPO plans Monday morning, mapping out what could be one of the biggest biotech IPOs in the past few years if it raises $370 million by pricing at the high end of its proposed range. The California biotech aims to sell 20.6 million shares of common

More

EndPoints News

Rare blood disorders biotech Hemab raises $135M, begins trek into clinic

Hemab Therapeutics, led by Alnylam vet Benny Sorensen and chaired by John Maraganore, has raised $135 million from a new crop of investors as it begins pushing its blood disorder programs into the clinic. Hemab’s Series B was led by Access Biotechnology, followed by Deep Track Capital, Avoro Capital, Invus, Rock Springs Capital and Danish

More

Endpoints News

PROTACs to RIPTACs: Arvinas founder snags $76M for next bet, Halda Therapeutics

A leader in the protein degradation space, Yale’s Craig Crews, is back with another biotech, Halda Therapeutics. On Tuesday, the startup announced $76 million in funding to take forward a new technology out of Crews’ lab, called RIPTACs, or Regulated Induced Proximity TArgeting Chimeras. The 26-employee startup emerged from hid decades-long work on heterobifunctional molecules,

More

Wall Street Journal

Biotech Startup Acelyrin Buys Drugmaker ValenzaBio in Stock Deal

Acelyrin said it acquired privately held ValenzaBio in an all-stock transaction but didn’t disclose further financial details of the acquisition. Acelyrin, which disclosed a $300 million venture financing in September led by Access Biotechnology, previously struck a deal with biotech Affibody AB to secure global rights to develop and commercialize a compound, izokibep, except in

More

Endpoints News

Verona says second PhIII for COPD drug hits the mark, plans 2023 NDA filing

UK-based biotech Verona Pharma said Tuesday morning that its drug, ensifentrine, passed its second late-stage trial for the common lung disease COPD. In August, Verona reported the drug succeeded in the first of its two Phase III trials. Now, Verona will package together the new trial data in its approval filing to the FDA, which

More